nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0346	0.0435	CbGbCtD
Tolterodine—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0326	0.0409	CbGbCtD
Tolterodine—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0295	0.037	CbGbCtD
Tolterodine—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0295	0.037	CbGbCtD
Tolterodine—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0288	0.0362	CbGbCtD
Tolterodine—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0271	0.034	CbGbCtD
Tolterodine—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0271	0.034	CbGbCtD
Tolterodine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0263	0.0331	CbGbCtD
Tolterodine—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0254	0.0319	CbGbCtD
Tolterodine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0248	0.0311	CbGbCtD
Tolterodine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0248	0.0311	CbGbCtD
Tolterodine—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0247	0.031	CbGbCtD
Tolterodine—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0245	0.0308	CbGbCtD
Tolterodine—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0245	0.0308	CbGbCtD
Tolterodine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0224	0.0281	CbGbCtD
Tolterodine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0224	0.0281	CbGbCtD
Tolterodine—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0223	0.028	CbGbCtD
Tolterodine—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0223	0.028	CbGbCtD
Tolterodine—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0214	0.0269	CbGbCtD
Tolterodine—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0211	0.0266	CbGbCtD
Tolterodine—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0205	0.0258	CbGbCtD
Tolterodine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0193	0.0243	CbGbCtD
Tolterodine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0188	0.0236	CbGbCtD
Tolterodine—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0186	0.0233	CbGbCtD
Tolterodine—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0186	0.0233	CbGbCtD
Tolterodine—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0178	0.0223	CbGbCtD
Tolterodine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.017	0.0213	CbGbCtD
Tolterodine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.017	0.0213	CbGbCtD
Tolterodine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0167	0.021	CbGbCtD
Tolterodine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0157	0.0198	CbGbCtD
Tolterodine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0157	0.0198	CbGbCtD
Tolterodine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0142	0.0179	CbGbCtD
Tolterodine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0142	0.0179	CbGbCtD
Tolterodine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0123	0.0154	CbGbCtD
Tolterodine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0119	0.015	CbGbCtD
Tolterodine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0108	0.0136	CbGbCtD
Tolterodine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0108	0.0136	CbGbCtD
Tolterodine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0103	0.013	CbGbCtD
Tolterodine—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00125	0.0593	CbGeAlD
Tolterodine—CHRM5—skin of body—acquired immunodeficiency syndrome	0.00116	0.0549	CbGeAlD
Tolterodine—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000971	0.046	CbGeAlD
Tolterodine—CHRM4—nervous system—acquired immunodeficiency syndrome	0.000916	0.0434	CbGeAlD
Tolterodine—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.000882	0.0418	CbGeAlD
Tolterodine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00074	0.0351	CbGeAlD
Tolterodine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000728	0.0345	CbGeAlD
Tolterodine—CHRM5—nervous system—acquired immunodeficiency syndrome	0.000716	0.034	CbGeAlD
Tolterodine—CHRM4—brain—acquired immunodeficiency syndrome	0.0007	0.0332	CbGeAlD
Tolterodine—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.00069	0.0327	CbGeAlD
Tolterodine—Anaphylactic shock—Nevirapine—acquired immunodeficiency syndrome	0.000605	0.00343	CcSEcCtD
Tolterodine—Gastrointestinal pain—Amprenavir—acquired immunodeficiency syndrome	0.000603	0.00342	CcSEcCtD
Tolterodine—Urinary tract infection—Ritonavir—acquired immunodeficiency syndrome	0.000601	0.00341	CcSEcCtD
Tolterodine—Arthralgia—Abacavir—acquired immunodeficiency syndrome	0.0006	0.0034	CcSEcCtD
Tolterodine—Anxiety—Abacavir—acquired immunodeficiency syndrome	0.000598	0.00339	CcSEcCtD
Tolterodine—Hallucination—Delavirdine—acquired immunodeficiency syndrome	0.000597	0.00339	CcSEcCtD
Tolterodine—Dysuria—Lamivudine—acquired immunodeficiency syndrome	0.000596	0.00338	CcSEcCtD
Tolterodine—Dry mouth—Stavudine—acquired immunodeficiency syndrome	0.000596	0.00338	CcSEcCtD
Tolterodine—Dyspepsia—Didanosine—acquired immunodeficiency syndrome	0.000592	0.00336	CcSEcCtD
Tolterodine—Oedema peripheral—Delavirdine—acquired immunodeficiency syndrome	0.000591	0.00336	CcSEcCtD
Tolterodine—Oedema—Nelfinavir—acquired immunodeficiency syndrome	0.000586	0.00332	CcSEcCtD
Tolterodine—Abdominal pain—Amprenavir—acquired immunodeficiency syndrome	0.000583	0.00331	CcSEcCtD
Tolterodine—Flushing—Efavirenz—acquired immunodeficiency syndrome	0.000582	0.0033	CcSEcCtD
Tolterodine—Sinusitis—Ritonavir—acquired immunodeficiency syndrome	0.00058	0.00329	CcSEcCtD
Tolterodine—Urinary tract infection—Saquinavir—acquired immunodeficiency syndrome	0.000579	0.00328	CcSEcCtD
Tolterodine—Anaphylactic shock—Abacavir—acquired immunodeficiency syndrome	0.000575	0.00326	CcSEcCtD
Tolterodine—Oedema—Abacavir—acquired immunodeficiency syndrome	0.000575	0.00326	CcSEcCtD
Tolterodine—Pain—Didanosine—acquired immunodeficiency syndrome	0.000575	0.00326	CcSEcCtD
Tolterodine—Infection—Abacavir—acquired immunodeficiency syndrome	0.000571	0.00324	CcSEcCtD
Tolterodine—Flatulence—Indinavir—acquired immunodeficiency syndrome	0.00057	0.00323	CcSEcCtD
Tolterodine—Angioedema—Zidovudine—acquired immunodeficiency syndrome	0.000568	0.00322	CcSEcCtD
Tolterodine—Vertigo—Zidovudine—acquired immunodeficiency syndrome	0.000559	0.00317	CcSEcCtD
Tolterodine—Sinusitis—Saquinavir—acquired immunodeficiency syndrome	0.000559	0.00317	CcSEcCtD
Tolterodine—Hallucination—Ritonavir—acquired immunodeficiency syndrome	0.000552	0.00313	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Nevirapine—acquired immunodeficiency syndrome	0.000551	0.00313	CcSEcCtD
Tolterodine—Gastrointestinal pain—Didanosine—acquired immunodeficiency syndrome	0.00055	0.00312	CcSEcCtD
Tolterodine—CHRM5—brain—acquired immunodeficiency syndrome	0.000548	0.026	CbGeAlD
Tolterodine—Oedema peripheral—Ritonavir—acquired immunodeficiency syndrome	0.000547	0.0031	CcSEcCtD
Tolterodine—Flatulence—Efavirenz—acquired immunodeficiency syndrome	0.000538	0.00305	CcSEcCtD
Tolterodine—Somnolence—Nevirapine—acquired immunodeficiency syndrome	0.000538	0.00305	CcSEcCtD
Tolterodine—Visual impairment—Ritonavir—acquired immunodeficiency syndrome	0.000535	0.00304	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Nelfinavir—acquired immunodeficiency syndrome	0.000534	0.00303	CcSEcCtD
Tolterodine—Sinusitis—Lamivudine—acquired immunodeficiency syndrome	0.000533	0.00302	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Stavudine—acquired immunodeficiency syndrome	0.000532	0.00302	CcSEcCtD
Tolterodine—Hallucination—Saquinavir—acquired immunodeficiency syndrome	0.000532	0.00302	CcSEcCtD
Tolterodine—Abdominal pain—Didanosine—acquired immunodeficiency syndrome	0.000532	0.00302	CcSEcCtD
Tolterodine—Arthralgia—Zidovudine—acquired immunodeficiency syndrome	0.000529	0.003	CcSEcCtD
Tolterodine—Chest pain—Zidovudine—acquired immunodeficiency syndrome	0.000529	0.003	CcSEcCtD
Tolterodine—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.000529	0.003	CcSEcCtD
Tolterodine—Angioedema—Indinavir—acquired immunodeficiency syndrome	0.000528	0.003	CcSEcCtD
Tolterodine—Anxiety—Zidovudine—acquired immunodeficiency syndrome	0.000527	0.00299	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Abacavir—acquired immunodeficiency syndrome	0.000524	0.00297	CcSEcCtD
Tolterodine—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.000521	0.00296	CcSEcCtD
Tolterodine—Somnolence—Nelfinavir—acquired immunodeficiency syndrome	0.000521	0.00295	CcSEcCtD
Tolterodine—Vertigo—Indinavir—acquired immunodeficiency syndrome	0.000519	0.00295	CcSEcCtD
Tolterodine—Somnolence—Stavudine—acquired immunodeficiency syndrome	0.000519	0.00294	CcSEcCtD
Tolterodine—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000518	0.0245	CbGeAlD
Tolterodine—Pain—Nevirapine—acquired immunodeficiency syndrome	0.000517	0.00293	CcSEcCtD
Tolterodine—Dyspepsia—Nelfinavir—acquired immunodeficiency syndrome	0.000515	0.00292	CcSEcCtD
Tolterodine—Flushing—Ritonavir—acquired immunodeficiency syndrome	0.000515	0.00292	CcSEcCtD
Tolterodine—Flatulence—Delavirdine—acquired immunodeficiency syndrome	0.000515	0.00292	CcSEcCtD
Tolterodine—Visual impairment—Saquinavir—acquired immunodeficiency syndrome	0.000515	0.00292	CcSEcCtD
Tolterodine—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.000514	0.00292	CcSEcCtD
Tolterodine—Confusional state—Zidovudine—acquired immunodeficiency syndrome	0.000512	0.0029	CcSEcCtD
Tolterodine—Palpitations—Indinavir—acquired immunodeficiency syndrome	0.000511	0.0029	CcSEcCtD
Tolterodine—Anaphylactic shock—Zidovudine—acquired immunodeficiency syndrome	0.000507	0.00288	CcSEcCtD
Tolterodine—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.000507	0.00288	CcSEcCtD
Tolterodine—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000505	0.00286	CcSEcCtD
Tolterodine—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000503	0.00286	CcSEcCtD
Tolterodine—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000501	0.00284	CcSEcCtD
Tolterodine—Pain—Stavudine—acquired immunodeficiency syndrome	0.000499	0.00283	CcSEcCtD
Tolterodine—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000499	0.00283	CcSEcCtD
Tolterodine—Angioedema—Efavirenz—acquired immunodeficiency syndrome	0.000499	0.00283	CcSEcCtD
Tolterodine—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.000498	0.00283	CcSEcCtD
Tolterodine—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000496	0.00281	CcSEcCtD
Tolterodine—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.000495	0.00281	CcSEcCtD
Tolterodine—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.000494	0.0028	CcSEcCtD
Tolterodine—Arthralgia—Indinavir—acquired immunodeficiency syndrome	0.000492	0.00279	CcSEcCtD
Tolterodine—Chest pain—Indinavir—acquired immunodeficiency syndrome	0.000492	0.00279	CcSEcCtD
Tolterodine—Pain—Abacavir—acquired immunodeficiency syndrome	0.000492	0.00279	CcSEcCtD
Tolterodine—CHRM2—nervous system—acquired immunodeficiency syndrome	0.000492	0.0233	CbGeAlD
Tolterodine—Vertigo—Efavirenz—acquired immunodeficiency syndrome	0.000491	0.00278	CcSEcCtD
Tolterodine—Anxiety—Indinavir—acquired immunodeficiency syndrome	0.000491	0.00278	CcSEcCtD
Tolterodine—CHRM1—lung—acquired immunodeficiency syndrome	0.000483	0.0229	CbGeAlD
Tolterodine—Palpitations—Efavirenz—acquired immunodeficiency syndrome	0.000483	0.00274	CcSEcCtD
Tolterodine—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.000483	0.00274	CcSEcCtD
Tolterodine—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000482	0.00274	CcSEcCtD
Tolterodine—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000481	0.00273	CcSEcCtD
Tolterodine—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000481	0.0228	CbGeAlD
Tolterodine—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000479	0.00272	CcSEcCtD
Tolterodine—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000478	0.00271	CcSEcCtD
Tolterodine—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.000478	0.00271	CcSEcCtD
Tolterodine—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000477	0.00271	CcSEcCtD
Tolterodine—Flatulence—Ritonavir—acquired immunodeficiency syndrome	0.000476	0.0027	CcSEcCtD
Tolterodine—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.000474	0.00269	CcSEcCtD
Tolterodine—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.000473	0.0224	CbGeAlD
Tolterodine—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.000472	0.00268	CcSEcCtD
Tolterodine—Oedema—Indinavir—acquired immunodeficiency syndrome	0.000472	0.00268	CcSEcCtD
Tolterodine—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.00047	0.00267	CcSEcCtD
Tolterodine—Vertigo—Delavirdine—acquired immunodeficiency syndrome	0.00047	0.00266	CcSEcCtD
Tolterodine—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	0.000465	0.00264	CcSEcCtD
Tolterodine—Chest pain—Efavirenz—acquired immunodeficiency syndrome	0.000465	0.00264	CcSEcCtD
Tolterodine—Anxiety—Efavirenz—acquired immunodeficiency syndrome	0.000463	0.00263	CcSEcCtD
Tolterodine—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000463	0.00263	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000462	0.00262	CcSEcCtD
Tolterodine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000462	0.00262	CcSEcCtD
Tolterodine—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.000462	0.00262	CcSEcCtD
Tolterodine—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000461	0.00262	CcSEcCtD
Tolterodine—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00046	0.00261	CcSEcCtD
Tolterodine—CYP2C19—blood—acquired immunodeficiency syndrome	0.000459	0.0217	CbGeAlD
Tolterodine—Flatulence—Saquinavir—acquired immunodeficiency syndrome	0.000458	0.0026	CcSEcCtD
Tolterodine—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000455	0.00258	CcSEcCtD
Tolterodine—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000455	0.00258	CcSEcCtD
Tolterodine—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000451	0.00256	CcSEcCtD
Tolterodine—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.00045	0.00255	CcSEcCtD
Tolterodine—CHRM1—nervous system—acquired immunodeficiency syndrome	0.000448	0.0212	CbGeAlD
Tolterodine—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000447	0.00253	CcSEcCtD
Tolterodine—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000445	0.00253	CcSEcCtD
Tolterodine—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000445	0.00252	CcSEcCtD
Tolterodine—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.000445	0.00252	CcSEcCtD
Tolterodine—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000443	0.00252	CcSEcCtD
Tolterodine—KCNH2—blood—acquired immunodeficiency syndrome	0.000437	0.0207	CbGeAlD
Tolterodine—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000437	0.00248	CcSEcCtD
Tolterodine—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.000437	0.00248	CcSEcCtD
Tolterodine—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000435	0.00247	CcSEcCtD
Tolterodine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000435	0.00247	CcSEcCtD
Tolterodine—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000434	0.00246	CcSEcCtD
Tolterodine—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000434	0.00246	CcSEcCtD
Tolterodine—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000434	0.00246	CcSEcCtD
Tolterodine—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000434	0.00246	CcSEcCtD
Tolterodine—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000431	0.00245	CcSEcCtD
Tolterodine—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.000431	0.0204	CbGeAlD
Tolterodine—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.00043	0.00244	CcSEcCtD
Tolterodine—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.00043	0.00244	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.00043	0.00244	CcSEcCtD
Tolterodine—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000427	0.00242	CcSEcCtD
Tolterodine—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000427	0.00242	CcSEcCtD
Tolterodine—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000425	0.0202	CbGeAlD
Tolterodine—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000424	0.0024	CcSEcCtD
Tolterodine—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000424	0.0024	CcSEcCtD
Tolterodine—KCNH2—bone marrow—acquired immunodeficiency syndrome	0.000423	0.0201	CbGeAlD
Tolterodine—KCNH2—spinal cord—acquired immunodeficiency syndrome	0.000421	0.02	CbGeAlD
Tolterodine—Headache—Didanosine—acquired immunodeficiency syndrome	0.000421	0.00239	CcSEcCtD
Tolterodine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00042	0.00238	CcSEcCtD
Tolterodine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.00042	0.00238	CcSEcCtD
Tolterodine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000419	0.00238	CcSEcCtD
Tolterodine—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000418	0.00237	CcSEcCtD
Tolterodine—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000418	0.00237	CcSEcCtD
Tolterodine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000416	0.00236	CcSEcCtD
Tolterodine—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000415	0.00236	CcSEcCtD
Tolterodine—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000415	0.00235	CcSEcCtD
Tolterodine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000414	0.00235	CcSEcCtD
Tolterodine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000413	0.00234	CcSEcCtD
Tolterodine—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000412	0.00233	CcSEcCtD
Tolterodine—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000412	0.00233	CcSEcCtD
Tolterodine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.00041	0.00233	CcSEcCtD
Tolterodine—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000407	0.00231	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000406	0.0023	CcSEcCtD
Tolterodine—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000406	0.0023	CcSEcCtD
Tolterodine—KCNH2—vagina—acquired immunodeficiency syndrome	0.000406	0.0192	CbGeAlD
Tolterodine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000404	0.00229	CcSEcCtD
Tolterodine—Pain—Indinavir—acquired immunodeficiency syndrome	0.000404	0.00229	CcSEcCtD
Tolterodine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000402	0.00228	CcSEcCtD
Tolterodine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000401	0.00228	CcSEcCtD
Tolterodine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000401	0.00227	CcSEcCtD
Tolterodine—CHRM3—nervous system—acquired immunodeficiency syndrome	0.000401	0.019	CbGeAlD
Tolterodine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000399	0.00227	CcSEcCtD
Tolterodine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000399	0.00226	CcSEcCtD
Tolterodine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000398	0.00226	CcSEcCtD
Tolterodine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000396	0.00225	CcSEcCtD
Tolterodine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000396	0.00225	CcSEcCtD
Tolterodine—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000396	0.00225	CcSEcCtD
Tolterodine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000395	0.00224	CcSEcCtD
Tolterodine—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000394	0.00224	CcSEcCtD
Tolterodine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000393	0.00223	CcSEcCtD
Tolterodine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000392	0.00223	CcSEcCtD
Tolterodine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000389	0.00221	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000389	0.0022	CcSEcCtD
Tolterodine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000387	0.0022	CcSEcCtD
Tolterodine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000387	0.0022	CcSEcCtD
Tolterodine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000386	0.00219	CcSEcCtD
Tolterodine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000386	0.00219	CcSEcCtD
Tolterodine—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000386	0.0183	CbGeAlD
Tolterodine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000385	0.00218	CcSEcCtD
Tolterodine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000384	0.00218	CcSEcCtD
Tolterodine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000383	0.00217	CcSEcCtD
Tolterodine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000381	0.00216	CcSEcCtD
Tolterodine—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000381	0.00216	CcSEcCtD
Tolterodine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00038	0.00216	CcSEcCtD
Tolterodine—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.00038	0.00215	CcSEcCtD
Tolterodine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000379	0.00215	CcSEcCtD
Tolterodine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000379	0.00215	CcSEcCtD
Tolterodine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000378	0.00214	CcSEcCtD
Tolterodine—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000378	0.00214	CcSEcCtD
Tolterodine—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000377	0.00214	CcSEcCtD
Tolterodine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000377	0.00214	CcSEcCtD
Tolterodine—CHRM2—brain—acquired immunodeficiency syndrome	0.000376	0.0178	CbGeAlD
Tolterodine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000376	0.00213	CcSEcCtD
Tolterodine—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000373	0.0177	CbGeAlD
Tolterodine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000373	0.00212	CcSEcCtD
Tolterodine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00037	0.0021	CcSEcCtD
Tolterodine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000368	0.00209	CcSEcCtD
Tolterodine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000367	0.00208	CcSEcCtD
Tolterodine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000367	0.00208	CcSEcCtD
Tolterodine—Headache—Stavudine—acquired immunodeficiency syndrome	0.000366	0.00207	CcSEcCtD
Tolterodine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000365	0.00207	CcSEcCtD
Tolterodine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000365	0.00207	CcSEcCtD
Tolterodine—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000365	0.00207	CcSEcCtD
Tolterodine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000365	0.00207	CcSEcCtD
Tolterodine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000364	0.00207	CcSEcCtD
Tolterodine—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000362	0.00205	CcSEcCtD
Tolterodine—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000362	0.00205	CcSEcCtD
Tolterodine—Headache—Abacavir—acquired immunodeficiency syndrome	0.00036	0.00204	CcSEcCtD
Tolterodine—Infection—Lamivudine—acquired immunodeficiency syndrome	0.00036	0.00204	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000359	0.00204	CcSEcCtD
Tolterodine—CYP2C9—blood—acquired immunodeficiency syndrome	0.000356	0.0169	CbGeAlD
Tolterodine—KCNH2—nervous system—acquired immunodeficiency syndrome	0.000355	0.0168	CbGeAlD
Tolterodine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000352	0.002	CcSEcCtD
Tolterodine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000352	0.00199	CcSEcCtD
Tolterodine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000351	0.00199	CcSEcCtD
Tolterodine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000349	0.00198	CcSEcCtD
Tolterodine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000348	0.00197	CcSEcCtD
Tolterodine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000347	0.00197	CcSEcCtD
Tolterodine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000347	0.00197	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000346	0.00196	CcSEcCtD
Tolterodine—CHRM1—brain—acquired immunodeficiency syndrome	0.000342	0.0162	CbGeAlD
Tolterodine—KCNH2—central nervous system—acquired immunodeficiency syndrome	0.000342	0.0162	CbGeAlD
Tolterodine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.00034	0.00193	CcSEcCtD
Tolterodine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000339	0.00192	CcSEcCtD
Tolterodine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000338	0.00191	CcSEcCtD
Tolterodine—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000337	0.00191	CcSEcCtD
Tolterodine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000337	0.00191	CcSEcCtD
Tolterodine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000337	0.00191	CcSEcCtD
Tolterodine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000336	0.0019	CcSEcCtD
Tolterodine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000334	0.0019	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.00033	0.00187	CcSEcCtD
Tolterodine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000328	0.00186	CcSEcCtD
Tolterodine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000327	0.00186	CcSEcCtD
Tolterodine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000325	0.00184	CcSEcCtD
Tolterodine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000325	0.00184	CcSEcCtD
Tolterodine—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000325	0.00184	CcSEcCtD
Tolterodine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000323	0.00183	CcSEcCtD
Tolterodine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000323	0.00183	CcSEcCtD
Tolterodine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000322	0.00183	CcSEcCtD
Tolterodine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00032	0.00181	CcSEcCtD
Tolterodine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000319	0.00181	CcSEcCtD
Tolterodine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000318	0.0018	CcSEcCtD
Tolterodine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000314	0.00178	CcSEcCtD
Tolterodine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000313	0.00178	CcSEcCtD
Tolterodine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000312	0.00177	CcSEcCtD
Tolterodine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000312	0.00177	CcSEcCtD
Tolterodine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000312	0.00177	CcSEcCtD
Tolterodine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.00031	0.00176	CcSEcCtD
Tolterodine—Pain—Lamivudine—acquired immunodeficiency syndrome	0.00031	0.00176	CcSEcCtD
Tolterodine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.00031	0.00176	CcSEcCtD
Tolterodine—CHRM3—brain—acquired immunodeficiency syndrome	0.000306	0.0145	CbGeAlD
Tolterodine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000306	0.00174	CcSEcCtD
Tolterodine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000305	0.00173	CcSEcCtD
Tolterodine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.0003	0.0017	CcSEcCtD
Tolterodine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000298	0.00169	CcSEcCtD
Tolterodine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000296	0.00168	CcSEcCtD
Tolterodine—Headache—Indinavir—acquired immunodeficiency syndrome	0.000296	0.00168	CcSEcCtD
Tolterodine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000295	0.00167	CcSEcCtD
Tolterodine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000292	0.00166	CcSEcCtD
Tolterodine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000291	0.00165	CcSEcCtD
Tolterodine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000286	0.00162	CcSEcCtD
Tolterodine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000285	0.0135	CbGeAlD
Tolterodine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000283	0.00161	CcSEcCtD
Tolterodine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000282	0.0016	CcSEcCtD
Tolterodine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.00028	0.0133	CbGeAlD
Tolterodine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00028	0.00159	CcSEcCtD
Tolterodine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000279	0.00158	CcSEcCtD
Tolterodine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.00155	CcSEcCtD
Tolterodine—KCNH2—brain—acquired immunodeficiency syndrome	0.000271	0.0129	CbGeAlD
Tolterodine—CYP3A4—blood—acquired immunodeficiency syndrome	0.000271	0.0129	CbGeAlD
Tolterodine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.00027	0.00153	CcSEcCtD
Tolterodine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000267	0.00152	CcSEcCtD
Tolterodine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000267	0.00151	CcSEcCtD
Tolterodine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000267	0.0126	CbGeAlD
Tolterodine—KCNH2—lymph node—acquired immunodeficiency syndrome	0.000262	0.0124	CbGeAlD
Tolterodine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000261	0.00148	CcSEcCtD
Tolterodine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.00147	CcSEcCtD
Tolterodine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00026	0.00147	CcSEcCtD
Tolterodine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000251	0.00142	CcSEcCtD
Tolterodine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000248	0.00141	CcSEcCtD
Tolterodine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000247	0.0014	CcSEcCtD
Tolterodine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00024	0.00136	CcSEcCtD
Tolterodine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000238	0.00135	CcSEcCtD
Tolterodine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000227	0.00129	CcSEcCtD
Tolterodine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.00022	0.0104	CbGeAlD
Tolterodine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000217	0.0103	CbGeAlD
Tolterodine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000212	0.01	CbGeAlD
Tolterodine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000209	0.00988	CbGeAlD
Tolterodine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000166	0.00785	CbGeAlD
Tolterodine—CHRM2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	2.61e-05	0.00413	CbGpPWpGaD
Tolterodine—CHRM2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	2.61e-05	0.00413	CbGpPWpGaD
Tolterodine—CHRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	2.61e-05	0.00413	CbGpPWpGaD
Tolterodine—CHRM3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	2.6e-05	0.00411	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	2.58e-05	0.00408	CbGpPWpGaD
Tolterodine—CHRM2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	2.58e-05	0.00407	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	2.57e-05	0.00407	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	2.55e-05	0.00403	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.52e-05	0.00399	CbGpPWpGaD
Tolterodine—CHRM4—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.49e-05	0.00394	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	2.47e-05	0.00391	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	2.46e-05	0.0039	CbGpPWpGaD
Tolterodine—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	2.45e-05	0.00388	CbGpPWpGaD
Tolterodine—CHRM3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	2.45e-05	0.00387	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	2.44e-05	0.00386	CbGpPWpGaD
Tolterodine—CHRM2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	2.42e-05	0.00383	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.42e-05	0.00382	CbGpPWpGaD
Tolterodine—CHRM5—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.39e-05	0.00378	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.37e-05	0.00375	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.37e-05	0.00375	CbGpPWpGaD
Tolterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.37e-05	0.00375	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.32e-05	0.00367	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.27e-05	0.00359	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.27e-05	0.00359	CbGpPWpGaD
Tolterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.27e-05	0.00359	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.26e-05	0.00357	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	2.24e-05	0.00353	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	2.23e-05	0.00352	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.22e-05	0.00351	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	2.21e-05	0.00349	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.17e-05	0.00342	CbGpPWpGaD
Tolterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.14e-05	0.00338	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	2.1e-05	0.00332	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	2.1e-05	0.00332	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.1e-05	0.00332	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	2.09e-05	0.00331	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	2.09e-05	0.00331	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	2.07e-05	0.00328	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	2.07e-05	0.00328	CbGpPWpGaD
Tolterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.05e-05	0.00323	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.01e-05	0.00318	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.01e-05	0.00318	CbGpPWpGaD
Tolterodine—CHRM2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	1.99e-05	0.00314	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	1.96e-05	0.0031	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	1.88e-05	0.00298	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	1.88e-05	0.00297	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	1.86e-05	0.00294	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.83e-05	0.0029	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.81e-05	0.00285	CbGpPWpGaD
Tolterodine—CHRM2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	1.79e-05	0.00283	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.73e-05	0.00273	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.7e-05	0.00269	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.7e-05	0.00268	CbGpPWpGaD
Tolterodine—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.68e-05	0.00266	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.68e-05	0.00266	CbGpPWpGaD
Tolterodine—CHRM3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.68e-05	0.00265	CbGpPWpGaD
Tolterodine—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.66e-05	0.00262	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.63e-05	0.00257	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—TAT—acquired immunodeficiency syndrome	1.62e-05	0.00256	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.6e-05	0.00253	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.6e-05	0.00253	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.6e-05	0.00253	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.6e-05	0.00252	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.6e-05	0.00252	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.59e-05	0.00252	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.58e-05	0.0025	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.58e-05	0.0025	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.58e-05	0.0025	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.58e-05	0.0025	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.56e-05	0.00247	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.56e-05	0.00246	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.56e-05	0.00246	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.54e-05	0.00244	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.52e-05	0.00241	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.52e-05	0.0024	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.5e-05	0.00238	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.44e-05	0.00228	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.44e-05	0.00227	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.43e-05	0.00226	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.43e-05	0.00226	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.42e-05	0.00225	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.41e-05	0.00224	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.41e-05	0.00223	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.4e-05	0.00221	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—AGPS—acquired immunodeficiency syndrome	1.38e-05	0.00218	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.37e-05	0.00217	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.37e-05	0.00217	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.37e-05	0.00217	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.37e-05	0.00216	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.34e-05	0.00212	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.34e-05	0.00212	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.31e-05	0.00207	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.31e-05	0.00207	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.3e-05	0.00205	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.28e-05	0.00203	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.28e-05	0.00203	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.24e-05	0.00196	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.24e-05	0.00196	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.22e-05	0.00193	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.22e-05	0.00193	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.22e-05	0.00193	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.21e-05	0.00192	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.2e-05	0.0019	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.19e-05	0.00188	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.17e-05	0.00184	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.17e-05	0.00184	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.1e-05	0.00173	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.09e-05	0.00173	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.08e-05	0.00171	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	1.05e-05	0.00166	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	1.04e-05	0.00165	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.02e-05	0.00161	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.01e-05	0.00159	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.77e-06	0.00155	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	9.69e-06	0.00153	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.66e-06	0.00153	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.63e-06	0.00152	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.63e-06	0.00152	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.62e-06	0.00152	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	9.6e-06	0.00152	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.59e-06	0.00152	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.53e-06	0.00151	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.5e-06	0.0015	CbGpPWpGaD
Tolterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	9.38e-06	0.00148	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	9.27e-06	0.00147	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.24e-06	0.00146	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.24e-06	0.00146	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.21e-06	0.00146	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.21e-06	0.00146	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.19e-06	0.00145	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.13e-06	0.00144	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.12e-06	0.00144	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.12e-06	0.00144	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.04e-06	0.00143	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.04e-06	0.00143	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.02e-06	0.00143	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.02e-06	0.00143	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	8.95e-06	0.00142	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.93e-06	0.00141	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.93e-06	0.00141	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.87e-06	0.0014	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.8e-06	0.00139	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.74e-06	0.00138	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.74e-06	0.00138	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.71e-06	0.00138	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.62e-06	0.00136	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.46e-06	0.00134	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	8.43e-06	0.00133	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.35e-06	0.00132	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.35e-06	0.00132	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.33e-06	0.00132	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.25e-06	0.0013	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	8.24e-06	0.0013	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.21e-06	0.0013	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.21e-06	0.0013	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.19e-06	0.00129	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.19e-06	0.00129	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	8.16e-06	0.00129	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.11e-06	0.00128	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.11e-06	0.00128	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.1e-06	0.00128	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.99e-06	0.00126	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.65e-06	0.00121	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.33e-06	0.00116	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.2e-06	0.00114	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.2e-06	0.00114	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	6.97e-06	0.0011	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.89e-06	0.00109	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.89e-06	0.00109	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.88e-06	0.00109	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.86e-06	0.00108	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.79e-06	0.00107	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.78e-06	0.00107	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.76e-06	0.00107	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.69e-06	0.00106	CbGpPWpGaD
Tolterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.61e-06	0.00104	CbGpPWpGaD
Tolterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.59e-06	0.00104	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	6.33e-06	0.001	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.25e-06	0.000988	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.23e-06	0.000985	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.2e-06	0.00098	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.18e-06	0.000977	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.17e-06	0.000975	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.15e-06	0.000973	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.13e-06	0.00097	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.12e-06	0.000967	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.08e-06	0.000961	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.71e-06	0.000902	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.69e-06	0.000899	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.63e-06	0.000891	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.63e-06	0.00089	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.61e-06	0.000887	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.56e-06	0.000879	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.47e-06	0.000865	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.39e-06	0.000853	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	5.38e-06	0.000851	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.31e-06	0.00084	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.24e-06	0.000829	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.16e-06	0.000816	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.16e-06	0.000816	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.14e-06	0.000813	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.09e-06	0.000805	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.09e-06	0.000804	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.93e-06	0.00078	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.85e-06	0.000767	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.85e-06	0.000767	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.84e-06	0.000765	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.84e-06	0.000765	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.82e-06	0.000763	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.79e-06	0.000757	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.79e-06	0.000757	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.72e-06	0.000747	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.62e-06	0.00073	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.12e-06	0.000652	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.76e-06	0.000594	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.69e-06	0.000584	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.68e-06	0.000582	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.64e-06	0.000576	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.64e-06	0.000575	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.62e-06	0.000573	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.59e-06	0.000567	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.58e-06	0.000566	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.57e-06	0.000564	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.54e-06	0.000559	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.33e-06	0.000526	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.31e-06	0.000524	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.28e-06	0.000519	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.25e-06	0.000514	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.24e-06	0.000513	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.21e-06	0.000508	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.85e-06	0.000451	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.84e-06	0.000448	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	2.82e-06	0.000447	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.73e-06	0.000431	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.72e-06	0.000429	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.92e-06	0.000304	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.92e-06	0.000303	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.91e-06	0.000302	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.91e-06	0.000301	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.9e-06	0.0003	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.89e-06	0.000298	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	1.84e-06	0.00029	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.69e-06	0.000267	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.67e-06	0.000265	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	1.67e-06	0.000265	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.6e-06	0.000254	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.13e-06	0.000179	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.13e-06	0.000178	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.11e-06	0.000176	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.1e-06	0.000175	CbGpPWpGaD
